Delic’s First Acquisition in Bid to Become Psychedelic Clinic Leader
Ryan Allway
February 12th, 2021
Psychedelics, Top Story
The psychedelics industry is projected to reach nearly $7 billion by 2027, according to Data Bridge Market Research, representing a 16.3% compound annual growth rate. Most companies in the space are undergoing expensive preclinical and clinical trials to bring psilocybin and other psychedelics to market and treat unmet medical needs in mental health.
While psilocybin has been the primary focus, ketamine has been an approved anesthesia and acute pain management medication since the 1960s. The drug has been increasingly used off-label as a treatment for depression, and in 2019, the FDA approved an esketamine nasal spray to treat adults with major depressive disorder and acute suicidal ideation or behavior.
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) in part, focusing on rolling up ketamine clinics across the country as a way to generate immediate cash flow in the psychedelics space with an existing FDA approved drug rather than going through expensive and time-consuming clinical trials. As additional psychedelic compounds are approved, these legal and established clinics could quickly expand their focus to serve client needs including PTSD, depression, anxiety and even bi-polar disorder.
The Beginning of a Roll-up Strategy
Delic has sought to expand from a central hub of psychedelics education, media and information to providing patients with psychedelic therapy through a planned roll-up and further acquisition strategy.
The company recently made its inaugural acquisition of Ketamine Infusion Centers LLC, which operates two ketamine infusion treatment clinics in Arizona and California. Since 2019, the company has generated $1.5 million in revenue with an experienced management team and six medical professionals that bring a wealth of industry knowledge and experience.
Click here to receive an investor presentation and corporate updates
Ketamine Infusion Centers LLC Offices
It’s not the Number of Clinics, This is an Experienced Team of Professionals That can Expand This Business Model Far and Beyond
“Our management team has been in the clinic and medical business for 15 years scaling and operating,” said KIC Co-Founder Sonny Diaz. “We jumped on the opportunity to join Delic as we feel the patient acquisition strategy—using Delic’s media platform to drive patients—is a potential game-changer. We think there is an opportunity to scale our SOPs and clinics over the next 18 months to be the national leader in the space.”
In addition to adding incremental revenue, the acquisition augments Delic’s management team with knowledge and experience in the ketamine clinic space. The company plans to use KIC’s best practices, including an insurance reimbursement program, to scale out its clinic footprint throughout the country over the coming quarters.
Unique Marketing Exposure
Delic has built an established education, media, and information presence through its Reality Sandwich education platform, Meet Delic wellness summit, and The Delic e-commerce brand.
Company management was responsible for helping High Times become the household cannabis brand that it is today. By leveraging that experience and in-depth industry relationships and its media business, the company aims to bring attention and awareness to its growing network of ketamine clinics as it pursues a roll-up acquisition and organic expansion strategy.
Reality Sandwich Education Portal
“From my years at High Times helping build the household cannabis brands of today, we know that in a nascent industry, whoever yells the loudest gets attention,” said Delic Founder and CEO Matt Stang. “Our media exposure and expertise is second to none in the industry and we feel like we can give a tremendous amount of attention to KIC and all future companies that join the Delic ecosystem.”
Looking Ahead
Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) made an inaugural acquisition that marks the beginning of a roll-up strategy in the ketamine clinic space. In addition to immediate cash flow, the company plans to leverage its media business to create awareness around the clinics and eventually become a nationwide leader in the space.
Click here to receive an investor presentation and corporate updates
Disclaimer
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Tom Zuber is Zuber Lawler & Del Duca’s Managing Partner. He has a degree with highest honors in biomedical engineering and has advised some of the most iconic companies in the world on their patent and trademark portfolios. He is at the cutting edge of cannabis patent and trademark law. He holds degrees from Harvard University and Columbia Law […]
Tryp Therapeutics is a pharmaceutical company focused on developing compounds with known activity and/or safety profiles for the treatment of rare diseases and other diseases with high unmet medical needs.
EuroMed Therapeutics is building the ninth Israeli licensed producer to capitalize on the domestic medical marijuana market and Europe’s nascent export market — worth upwards of $66 billion.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
